Identification of metabolites of Zhali Nusi Prescription in rat plasma, bile, urine and feces after oral administration.
10.19540/j.cnki.cjcmm.20200623.201
- Author:
Ting ZHANG
1
;
Yang NIU
2
;
Kai-Di HUANG
3
;
B U FAN-SHU
3
;
Xiao-Kun BIAN
4
;
Qiu-Long ZHAO
4
;
Sheng GUO
1
;
Er-Xin SHANG
3
;
Da-Wei QIAN
1
;
Jin-Ao DUAN
4
Author Information
1. Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine Nanjing 210023, China.
2. The Key Laboratory of Ministry of Education of Ningxia Medical University, Ningxia Medical University Yinchuan 750004, China.
3. Key Laboratory of Chinese Medicinal Resources Recycling Utilization, State Administration of Traditional Chinese Medicine, Nanjing University of Chinese Medicine Nanjing 210023, China.
4. National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine Nanjing 210023, China.
- Publication Type:Journal Article
- Keywords:
LTQ-Orbitrap-MS;
Zhali Nusi Prescription;
metabolite;
ultra high performance liquid chromatography
- MeSH:
Administration, Oral;
Animals;
Bile;
Chromatography, High Pressure Liquid;
Feces;
Plasma;
Prescriptions;
Rats
- From:
China Journal of Chinese Materia Medica
2020;45(21):5280-5288
- CountryChina
- Language:Chinese
-
Abstract:
This study was designed to determine the metabolites of Zhali Nusi Prescription(ZLNSP) in rats. The ultra-high performance liquid chromatography-LTQ Orbitrap mass spectrometric(UHPLC-LTQ-Orbitrap-MS) and mass defect filter techniques were applied to analyze the metabolites of ZLNSP in rat plasma, bile, urine and feces. The biological samples were analyzed by ACQUITY UPLC BEH T_3 column(2.1 mm×100 mm,1.7 μm), with 0.1% formic acid water(A)-acetonitrile(B) as mobile phase, and the biological samples were analyzed in negative ion mode by electrospray ionization mass spectrometry(ESI-MS). An analytical method for biological samples of rats was established, and 8 prototype components and 36 metabolites were identified. The results showed that the metabolic pathways of the main components of ZLNSP in rats included methylation, glucuronidation, sulfation and so on. It provi-ded information for the therapeutic effect of ZLNSP in vivo.
